Cardiomyopathy and echocardiographic abnormalities in Indian patients with psoriasis: Results of a pilot study.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
04
05
2020
accepted:
04
10
2020
pubmed:
17
10
2020
medline:
12
5
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
The relationship between psoriasis and cardiomyopathy is understudied in Indian patients. We evaluated psoriasis patients for cardiomyopathy and other echocardiographic abnormalities. About 98 (M:F = 67:31) patients with mild to moderate psoriasis aged 18-75 years (mean ± SD = 42.12 ± 12.79 years) having no pre-existing metabolic syndrome and cardiovascular disorders were studied. X-ray chest, electrocardiogram and echocardiography were performed and interpreted by cardiologist for size of the left and right ventricles, left ventricle ejection fraction, diastolic function, pulmonary artery pressure and valve abnormality/regurgitation and their severity as per current guidelines/recommendations. The cardiomyopathies were defined according to standard diagnostic guidelines. Echocardiographic abnormalities were noted in 13 (13.3%) patients aged 19-75 years (mean ± SD = 43.30 ± 15.71 years). The left ventricular diastolic dysfunction (grade 1) was observed in nine patients (moderate severe psoriasis in four patients) and one of them also had concentric left ventricular hypertrophy; a precursor of restrictive cardiomyopathy. Mild tricuspid valve regurgitation was present in other four patients. There was no statistically significant difference in age, gender, duration and the severity of psoriasis when compared with patients having normal echocardiography. The mitral or aortic valves, pulmonary artery pressure, mid-right-ventricular diameter and the left atrial volume showed no abnormality. Psoriasis perhaps plays a role in left ventricular dysfunction and possibly cardiomyopathy even with moderately severe disease and in the absence of clinical symptoms. However, these observations need to be interpreted with caution in the absence of any statistically significant difference between age, gender, duration and severity of psoriasis in the patients having normal and abnormal echocardiography.
Sections du résumé
BACKGROUND
BACKGROUND
The relationship between psoriasis and cardiomyopathy is understudied in Indian patients.
OBJECTIVE
OBJECTIVE
We evaluated psoriasis patients for cardiomyopathy and other echocardiographic abnormalities.
METHODS
METHODS
About 98 (M:F = 67:31) patients with mild to moderate psoriasis aged 18-75 years (mean ± SD = 42.12 ± 12.79 years) having no pre-existing metabolic syndrome and cardiovascular disorders were studied. X-ray chest, electrocardiogram and echocardiography were performed and interpreted by cardiologist for size of the left and right ventricles, left ventricle ejection fraction, diastolic function, pulmonary artery pressure and valve abnormality/regurgitation and their severity as per current guidelines/recommendations. The cardiomyopathies were defined according to standard diagnostic guidelines.
RESULTS
RESULTS
Echocardiographic abnormalities were noted in 13 (13.3%) patients aged 19-75 years (mean ± SD = 43.30 ± 15.71 years). The left ventricular diastolic dysfunction (grade 1) was observed in nine patients (moderate severe psoriasis in four patients) and one of them also had concentric left ventricular hypertrophy; a precursor of restrictive cardiomyopathy. Mild tricuspid valve regurgitation was present in other four patients. There was no statistically significant difference in age, gender, duration and the severity of psoriasis when compared with patients having normal echocardiography. The mitral or aortic valves, pulmonary artery pressure, mid-right-ventricular diameter and the left atrial volume showed no abnormality.
CONCLUSIONS
CONCLUSIONS
Psoriasis perhaps plays a role in left ventricular dysfunction and possibly cardiomyopathy even with moderately severe disease and in the absence of clinical symptoms. However, these observations need to be interpreted with caution in the absence of any statistically significant difference between age, gender, duration and severity of psoriasis in the patients having normal and abnormal echocardiography.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13756Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol. 2010;70:10-12.
Loo SKF, Yeung K, Ho K, Lo K. Cardiovascular comorbidities in psoriasis. Hong Kong J Dermatol Venereol. 2010;18:72-81.
Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140:1-7.
Basko-Plluska J, Petronic-Rosic V. Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis Targets Ther. 2012;2:67-76.
Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5-21.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol. 2000;53:95-102.
Farley E, Menter A. Psoriasis: co-morbidities and associations. G Ital Dermatol Venereol. 2011;146:9-15.
Chen Y-J, Shen J-L, Wu C-Y, Chang Y-T, Chen C-M, Lee F-Y. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 2009;60:225-230.
Badokin VV, Kotel’nikova GP. The heart damage in patients with psoriatic arthritis. Ter Arkh. 2004;76:56-61.
Eliakim-Raz N, Shuvy M, Lotan C, Planer D. Psoriasis and dilated cardiomyopathy: coincidence or associated diseases? Cardiology. 2008;111:202-206.
Lin H-W, Wang K-H, Lin H-C, Lin H-C. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64:495-501.
Ghiasi M, Nouri M, Abbasi A, Hatami P, Abbasi MA, Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol. 2011;56:533-536.
Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347-354.
Poorzand H, Birjandi MS, Taheri AR, et al. Comparison of echocardiographic abnormalities in psoriasis patients with the control group. J Cardio Thorac Med. 2016;4:509-512.
Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989;80:564-572.
Pietrzak A, Brzozowska A, Lotti T, et al. Future diagnosis, today’s treatment - cardiomyopathy in the course of psoriasis: a case report. Dermatol Ther. 2013;26:489-492.
Zhao CT, Yeung CK, Siu CW, et al. Relationship between parathyroid hormone and subclinical myocardial dysfunction in patients with severe psoriasis. J Eur Acad Dermatol Venereol. 2014;28:461-468.
Tanabe H, Maki Y, Urabe S, Higuchi I, Obayashi K, Hokezu Y. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case. Muscle Nerve. 2015;52:1113-1117.
Boehncke W-H, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 Annual Meeting. J Rheumatol. 2011;38:567-571.
Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30:535-544.
Prakash DA. Psoriasis and cardiomyopathy: An intriguing association. Indian J Dermatol. 2010;55:271-273.
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. 2004;15:27-29.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.
Tt M, Williams L, Navaratnam G, et al. On behalf of the British Society of Echocardiography Education Committee. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2017;4:G1-G13.
Elliott PM, Anastasakis A, Borger MA, et al. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733-2779.
Lakdawal NK, Stevenson LW, Loscalzo J. Cardiomyopathy and myocarditis. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Education; 2015:1553-1570.
Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline update for the Clinical Application of Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr. 2003;16:1091-1110.
Gottdiener JS, Bednarz J, Devereux R, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;10:1086-1119.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.
Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314.
Wadhwa D, Mahajan VK, Mehta KS, et al. Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case- control study. Arch Dermatol Res. 2019;311:287-297.
Rana A, Mahajan VK, Chauhan PS, et al. The association of thyroid dysfunction with chronic plaque psoriasis: a hospital based retrospective descriptive observational study. Indian Dermatol Online J. 2020;11:771-776.
Mastrolonardo M. Sympathetic nervous system dysfunction: a common pathway linking skin and heart morbidity? J Am Acad Dermatol. 2008;58:352.
Carvalho M, Soares R, Ribeiro F, et al. Rhythm profile in patients with psoriatic arthritis. Rev Port Cardiol. 1990;9:311-317.
Milaniuk S, Pietrzak A, Mosiewicz B, Mosiewicz J, Reich K. Influence of psoriasis on circulatory system function assessed in echocardiography. Arch Dermatol Res. 2015;307:855-861.
Biyik I, Narin A, Bozok M, Ergene O. Echocardiographic and clinical abnormalities in patients with psoriasis. J Int Med Res. 2006;34:632-639.
Kuznetsova T, Herbots L, Lóopez B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Cir Heart Fail. 2009;2:105-112.
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897-902.
Topilsky Y. Tricuspid valve regurgitation: epidemiology and pathophysiology. Minerva Cardioangiol. 2018;66:673-679.